March 2026 in “Frontiers in Pharmacology” This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
March 2026 in “Frontiers in Oncology” This study concluded that dermatologists are integral to the care of cancer survivors by shifting focus from symptomatic skin treatment to preventive and rehabilitative strategies that enhance long-term skin health and quality of life post-oncology therapy.
February 2026 in “Bioimpacts” This review discusses advancements and challenges in using 3D bioprinting for diabetic foot ulcer treatments, highlighting potential improvements and existing limitations in replicating skin architecture and clinical application.
February 2026 in “Frontiers in Bioengineering and Biotechnology” This review discusses the development of liposome-based delivery systems to enhance skin wound healing, highlighting their advantages and potential applications, but reports no new clinical results.
February 2026 in “Frontiers in Immunology” In this review, researchers detail how immunosenescence and chronic neuroinflammation contribute to Parkinson's disease progression, exploring potential therapeutic strategies targeting this axis, such as senolytic agents and immune rejuvenation, while highlighting associated challenges and future research needs.
February 2026 in “International Journal of Recent Surgical and Medical Sciences” This review highlights that both human-derived and plant-derived exosomes show anti-inflammatory and antioxidant properties, with human exosomes being better for targeted medicinal treatments due to their ability to transport healing drugs, while plant exosomes are more scalable and cost-effective for cosmetic applications.
February 2026 in “Frontiers in Medicine” This review discusses strategies to identify, prevent, and manage complications in FUE and reports no new clinical results.
January 2026 in “Frontiers in Digital Health” This study found that a motion-graphic educational video significantly improved patient knowledge during the informed consent process for platelet-rich plasma therapy in androgenetic alopecia compared to traditional verbal explanations, without affecting anxiety levels, and participants reported high satisfaction with the video.
This review reports that hair follicles are dynamic neuro-immuno-endocrine organs with intrinsic signaling pathways, which play a crucial role in hair disorders like alopecia. It highlights emerging regenerative approaches targeting these pathways for hair restoration.
January 2026 in “Frontiers in Drug Discovery” This study highlights that while advances in dermatology, such as biologics and JAK inhibitors, have improved treatments for conditions like atopic dermatitis and psoriasis, challenges remain, including issues with lasting efficacy and the need for more personalized therapies.
January 2026 in “International Journal of All Research Education & Scientific Methods” This review highlights recent advancements in understanding and treating alopecia, emphasizing genetic and immune factors involved in different forms, and discusses emerging therapies such as gene-editing and exosome-based treatments, though achieving complete hair regrowth remains a challenge.
December 2025 in “Eastern Ukrainian Medical Journal” This study reviews current methods for making and using platelet-rich plasma and fibrin, emphasizing the variability in clinical outcomes due to differences in preparation protocols, and calls for standardized guidelines and large-scale studies for better effectiveness in regenerative medicine.
December 2025 in “Cosmoderma” This study reviewed evidence suggesting that systemic corticosteroids, particularly in pulse regimens like dexamethasone and betamethasone oral mini-pulse, effectively slow vitiligo progression and support repigmentation, while offering a favorable safety profile compared to continuous therapy.
November 2025 in “International Journal of Zoology and Applied Biosciences” In this review, recent innovations in hair transplantation, such as AI-assisted graft selection, robotic systems, stem cell therapy, and advanced drug delivery techniques, are reported to enhance hair density and thickness for more natural results and higher patient satisfaction by addressing limitations of traditional methods.
November 2025 in “Frontiers in Immunology” This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.
October 2025 in “Frontiers in Immunology” This study explores the potential of platelet-rich plasma (PRP) as a novel adjuvant therapy for eczema, positing that it may alleviate inflammation, enhance skin barrier function, and reduce recurrence.
October 2025 in “Turkish Journal of Biochemistry” This study found that patients with tropical chronic pancreatitis exhibited significantly reduced plasma amino acid levels and antioxidant capacity, with folate deficiency identified as a key factor in hyperhomocysteinemia.
September 2025 in “Frontiers in Medicine” This study assessed the effectiveness of various combinations of minoxidil with other agents for androgenetic alopecia, finding that platelet-rich plasma and basic fibroblast growth factor combined with minoxidil significantly increased hair density, while different combinations were optimal depending on gender.
June 2025 in “Saratov Medical Journal” This review highlights recent advances in dermatology, including innovations in skin cancer treatments, acne and psoriasis management, trends in cosmetic procedures, and the impact of telemedicine, emphasizing ongoing research's role in enhancing patient care and outcomes.
January 2025 in “Directory of Open access Books (OAPEN Foundation)” This book reviews the symptoms, diagnosis, and treatments for Polycystic Ovary Syndrome, providing a comprehensive exploration but reports no new clinical results.
January 2025 in “il Diabete” This study explores potential strategies for targeted drug delivery specifically to pancreatic beta-cells in type 2 diabetes treatment, highlighting methods for inducing drug expression in beta-cells, suitable drug carriers, active targeting peptides, and optimal administration routes.
December 2024 in “International Journal of Maxillofacial Imaging” This abstract outlines the goal of various face cosmetic surgery procedures, such as rhinoplasty and facelifts, which are used to enhance facial appearance and address aging-related changes. However, specific study results are not provided.
September 2024 in “arXiv (Cornell University)” This study evaluated various NLP models for detecting bias in medical curricula, finding that fine-tuned BERT models perform well, whereas LLMs, despite being state-of-the-art in many tasks, are unsuitable for this application.
December 2023 in “Revista Urología Colombiana / Colombian Urology Journal” This systematic review found that treatments for sickle cell disease-related priapism are clinically diverse, with etilefrine, pseudoephedrine/etilefrine-5 inhibitors, and finasteride appearing promising, but further research with robust study designs is needed to establish evidence-based practices.
67 citations
,
January 2022 in “Theranostics” This review highlights how advanced nanocarrier and microneedle-based transdermal drug delivery strategies can potentially improve the treatment of skin diseases by enhancing site-specific drug delivery, increasing skin penetration, and reducing systemic toxicity compared to conventional methods.
48 citations
,
July 2001 in “Clinics in Dermatology” Cosmetics enhance beauty, fix defects, and intimidate enemies, with varying cultural standards and alternative methods.
4 citations
,
January 2022 in “Current pharmaceutical design” This review discusses the benefits and applications of microsponges delivery systems in drug delivery, particularly for topical treatments, and reports no new clinical findings.
November 2024 in “Communities in ADDI (University of the Basque Country)” Antisense oligonucleotides show promise for treating Myotonic Dystrophy type I.
This study found that elastin-like recombinamer (ELR) wound dressings promote tissue regeneration and stability without rejection in ex vivo and in vivo models, indicating potential for hard-to-heal wound treatment.
January 2023 in “International Journal of Pharmaceutical Research and Development” This review discusses alopecia, its pathophysiology, nanotechnology-based drug delivery systems, and related quality of life issues, without reporting new clinical results.